FindTrial
Sign In

Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting

Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2033240156
Enrollment
10
Registered
2024-06-13
Start date
2024-06-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with ischemic heart disease Ischemic heart disease, Heart Failure, Coronary artery bypass grafting (CABG)

Interventions

To take immunosuppressant tacrolimus or other immunosuppressant

Sponsors

Kaneko Takehiko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects who participated in the HS-001-01 study and were transplanted with HS-001CS and who were able to obtain voluntary consent in writing for inclusion in this clinical trial.

Exclusion criteria

Exclusion criteria: Patients judged by the Investigator to be ineligible shall not be included in the Clinical Trial.

Design outcomes

Primary

MeasureTime frame
Safety—

Secondary

MeasureTime frame
Safety—

Contacts

Public ContactMadoguchi Toiawase

Heartseed Inc

chiken@heartseed.jp+81-3-6380-1068

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026